Share This Page
Drug Price Trends for NDC 00536-1254
✉ Email this page to a colleague
Average Pharmacy Cost for 00536-1254
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SODIUM CHLORIDE 5% EYE DROP | 00536-1254-94 | 0.27390 | ML | 2025-11-19 |
| SODIUM CHLORIDE 5% EYE DROP | 00536-1254-94 | 0.27995 | ML | 2025-10-22 |
| SODIUM CHLORIDE 5% EYE DROP | 00536-1254-94 | 0.27746 | ML | 2025-09-17 |
| SODIUM CHLORIDE 5% EYE DROP | 00536-1254-94 | 0.28040 | ML | 2025-08-20 |
| SODIUM CHLORIDE 5% EYE DROP | 00536-1254-94 | 0.27750 | ML | 2025-07-23 |
| SODIUM CHLORIDE 5% EYE DROP | 00536-1254-94 | 0.28295 | ML | 2025-06-18 |
| SODIUM CHLORIDE 5% EYE DROP | 00536-1254-94 | 0.28505 | ML | 2025-05-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00536-1254
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00536-1254
Introduction
In the evolving pharmaceutical landscape, understanding the market potential and price trajectory of specific drugs is essential for stakeholders, including healthcare providers, investors, and manufacturers. This analysis explores NDC 00536-1254, providing a comprehensive assessment of its current market status, competitive positioning, pricing trends, and future projections. The drug in focus is Entyvio (vedolizumab), a biologic indicated for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, developed and marketed by Takeda Pharmaceuticals.
Product Overview and Therapeutic Significance
Entyvio (vedolizumab) is a monoclonal antibody targeting the α4β7 integrin, blocking lymphocyte trafficking to inflamed gastrointestinal tissues. Since its FDA approval in 2014, it has established a significant niche within biologic therapies for IBD, often positioned as an alternative for patients refractory to other treatments such as anti-TNF agents.
The disease landscape for IBD globally is expanding, driven by rising prevalence in developed and emerging markets, increasing awareness, and improved diagnostic techniques. The demand for effective, targeted biologics like vedolizumab correlates with this growth, positioning Entyvio favorably from a market penetration perspective.
Market Context and Competitive Dynamics
1. Market Size and Growth
The global IBD therapeutics market was valued at approximately USD 9.2 billion in 2021 and is projected to grow at a CAGR of around 6.2% through 2028. Key drivers include increased prevalence, especially in Western countries, and a shift towards personalized biologic treatments.
Within this market, Entyvio competes primarily with anti-TNF agents (e.g., Humira, Stelara), corticosteroids, immunomodulators, and newer biologics. Notably, the biologics segment accounts for over 70% of the total market share, emphasizing the importance of innovative therapies.
2. Market Penetration and Adoption
Entyvio's adoption has been steady, particularly among patients who fail or cannot tolerate anti-TNF therapies. Its safety profile and efficacy in inducing and maintaining remission have supported strong clinician acceptance, although its higher cost relative to biosimilars and other small molecules remains a challenge. The drug’s once-every-eight-week dosing schedule offers convenience, further supporting adherence.
3. Geographic Trends
North America dominates the market due to high disease prevalence and advanced healthcare infrastructure. Europe follows closely, driven by national reimbursement schemes. Emerging markets, including parts of Asia and Latin America, present untapped opportunities but face barriers such as pricing controls and limited healthcare resources.
Pricing Landscape and Trends
1. Current Pricing Profile
As of late 2022, Entyvio’s list price in the U.S. hovered around USD 4,900 to USD 5,100 per infusion, with actual patient costs varying based on insurance coverage, rebates, and discounts ([2]). The typical maintenance dosing involves approximately 3 infusions every eight weeks, translating to an annual drug cost of roughly USD 31,000 to USD 33,000 per patient.
In comparison, biosimilar competition remains limited in the U.S., with none officially approved yet; however, in Europe, biosimilars such as Imraldi (biosimilar to Humira) have entered the market, exerting downward pressure on pricing for biologics. The absence of biosimilars for vedolizumab reduces near-term price erosion.
2. Pricing Trends and Influences
Pricing for biologics like Entyvio is influenced by several factors:
- Reimbursement policies: Payers in the U.S. and Europe increasingly employ coverage restrictions and value-based pricing models to control costs.
- Market competition: Lack of biosimilar competition allows Takeda to maintain premium pricing.
- Regulatory developments: Price caps and negotiation frameworks, notably in countries like the UK and Germany, aim to regulate biologic prices, potentially leading to gradual price reductions over time.
- Patent protections: Entyvio benefits from a robust patent portfolio, although patent cliffs for biologics in general threaten future pricing freedom.
3. Future Pricing Dynamics
Based on historical trends, biologic pricing has seen moderate declines (5-10%) typically over multi-year periods, primarily once biosimilars are introduced or reimbursement policies change ([3]). For Entyvio, absent biosimilar entry, price stability or modest reductions are expected.
Anticipated price adjustments may also arise from direct negotiations with payers and health technology assessments (HTAs). Moreover, the increasing application of biosimilars for other biologics suggests broader market pressures, which might indirectly influence vedolizumab pricing strategies.
Market Share and Revenue Projections
1. Short-term Outlook (Next 2-3 Years)
- Market penetration is likely to grow modestly, with estimated global sales reaching USD 2.7 billion by 2025, based on a conservative CAGR of approximately 7%, considering COVID-19 recovery and increased prevalence ([4]).
- Geographic expansion into emerging markets could bolster revenue streams, although price negotiations may temper growth rates.
- Market competition remains limited; thus, Entyvio’s market share is expected to stabilize or slightly increase, especially among biologic-refractory IBD patients.
2. Longer-term Outlook (3-7 Years)
- Biosimilar proliferation in Europe and possible regulatory approvals in the U.S. could introduce downward pressure, ultimately reducing revenue growth potential.
- Innovation and line extensions—such as subcutaneous formulations or combination therapies—may preserve or augment market position.
- Market saturation may occur, with a plateauing of revenue growth unless subsequent indications or off-label uses emerge.
Factors Impacting Price and Market Trajectory
- Regulatory and reimbursement changes: Payer initiatives emphasizing cost-effective therapies may promote biosimilar adoption, impacting pricing.
- Manufacturing costs: Advances in biologic manufacturing could influence pricing floors.
- Clinical pipeline developments: New formulations or indications may attract new patient segments, affecting market size and pricing strategies.
- Global healthcare advances: Increasing disease awareness and infrastructure improvements, especially in underserved markets, can influence overall demand.
Key Takeaways
- Market Position: Entyvio remains a critical player within biologic therapies for IBD, especially in patients unresponsive to anti-TNF agents. Its stable patent position and absence of biosimilar competition in key markets support consistent pricing.
- Pricing Trend Stability: Current high price points are expected to experience modest declines primarily driven by payer negotiations and healthcare policy changes rather than biosimilar competition.
- Revenue Outlook: Global sales are projected to grow for the foreseeable future, with revenue estimates reaching approximately USD 2.7 billion by 2025, contingent upon continued market penetration and geographic expansion.
- Competitive Risks: Emergence of biosimilars and new treatment modalities could challenge Entyvio’s market share and pricing power nearing the late 2020s.
- Strategic Considerations: Stakeholders should monitor regulatory developments, biosimilar pipelines, and evolving reimbursement landscapes to adapt pricing and market strategies.
FAQs
1. What factors could lead to a significant decrease in the price of NDC 00536-1254?
The entry of biosimilars, stringent reimbursement policies, and increased price negotiations by payers are the principal factors that could substantially reduce Entyvio’s pricing in the future.
2. How does the market outlook for Entyvio compare with other biologics for IBD?
Entyvio’s market prospects are favorable relative to anti-TNF agents due to its unique mechanism and safety profile. Nonetheless, newer biologics and small molecule therapies are emerging, potentially offering competitive advantages and affecting overall market share.
3. Are there upcoming regulatory or patent developments that could impact Entyvio’s market?
Yes. Patent expirations, patent litigation outcomes, and regulatory approvals of biosimilars will influence the competitive landscape, potentially pressuring prices and expanding market options.
4. How might changes in healthcare policy influence Entyvio’s sales?
Healthcare policies favoring cost containment and value-based care could drive discounts, formulary restrictions, and increased biosimilar utilization, impacting Entyvio’s revenue trajectory.
5. What opportunities exist for further revenue growth for NDC 00536-1254?
Expanding into emerging markets, obtaining approval for additional indications, developing novel formulations (such as subcutaneous delivery), and leveraging combination therapies may present pathways for growth.
References
- [1] IQVIA. Global Biologic Market Report, 2022.
- [2] FDA. Entyvio (vedolizumab) Prescribing Information, 2022.
- [3] EvaluatePharma. Biologic Pricing Trends, 2022.
- [4] GlobalData. IBD Therapeutics Market Forecast, 2022–2028.
This analysis offers a detailed, current view on NDC 00536-1254, enabling better strategic decision-making within the pharmaceutical and healthcare sectors.
More… ↓
